Trial · NCT07907614
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Upper-limb functional capacity assessed by the DASH score at 6 weeks | 6 weeks after treatment initiation | Upper-limb functional capacity will be assessed using the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire. The DASH score at 6 weeks will be compared between the three study groups, with adjustment for the baseline DASH score. |
| Secondary | Upper-limb functional capacity assessed by the DASH score at 3 months after treatment | 3 months after the end of treatment (18 weeks after inclusion) | Upper-limb functional capacity will be assessed using the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire to evaluate the maintenance of treatment effects and compare the three study groups. |
| Secondary | Isometric elbow flexor and extensor muscle strength at 6 weeks | 6 weeks after treatment initiation | Isometric strength of the elbow flexor and extensor muscles will be measured and compared between the three study groups. |
| Secondary | Isometric elbow flexor ans extensor muscle strength at 3-month follow-up | 3 months after the end of treatment (18 weeks after inclusion) | Isometric strength of the elbow flexor and extensor muscles will be measured to assess the maintenance of treatment effects and compared between the three study groups. |
| Secondary | Active elbow and forearm range of motion at 6 weeks | 6 weeks after treatment initiation | Active elbow flexion and extension and forearm pronation and supination will be measured to assess changes in joint range of motion. |
| Secondary | Active elbow and forearm range of motion at 3-month follow-up | 3 months after the end of treatment (18 weeks after inclusion) | Active elbow flexion and extension and forearm pronation and supination will be measured to assess the maintenance of treatment effects. |
| Secondary | Pain intensity before and after rehabilitation sessions | Before and immediately after each rehabilitation session during the 6-week treatment period | Pain intensity will be assessed using a 0-10 numeric rating scale immediately before and after each rehabilitation session. The difference between pre-session and post-session pain scores will be assessed. |
| Secondary | Pain intensity at 6 weeks | 6 weeks after treatment initiation | Pain intensity will be assessed using a 0-10 numeric rating scale to compare pain at the end of the treatment period between the three study groups. |
| Secondary | Pain intensity at 3-month follow-up | 3 months after the end of treatment (18 weeks after inclusion) | Pain intensity will be assessed using a 0-10 numeric rating scale to evaluate the maintenance of treatment effects. |
| Secondary | Kinesiophobia assessed by the short TAMPA scale at 6 weeks | 6 weeks after treatment initiation | Kinesiophobia will be assessed using the short version of the Tampa Scale to compare the effects of the three rehabilitation protocols after treatment. |
| Secondary | Kinesiophobia assessed by the short TAMPA scale at 3-month follow-up | 3 months after the end of treatment (18 weeks after inclusion) | Kinesiophobia will be assessed using the short version of the Tampa Scale to evaluate the maintenance of treatment effects. |
| Secondary | Health-related quality of life assessed by the EQ-5D-5L at 6 weeks | 6 weeks after treatment initiation | Health-related quality of life will be assessed using the EQ-5D-5L questionnaire, including the health profile, EQ-5D index score, and EQ visual analogue scale (EQ-VAS). |
| Secondary | Health-related quality of life assessed by the EQ-5D-5L at 3-month follow-up | 3 months after the end of treatment (18 weeks after inclusion) | Health-related quality of life will be assessed using the EQ-5D-5L questionnaire, including the health profile, EQ-5D index score, and EQ visual analogue scale (EQ-VAS), to evaluate the maintenance of treatment effects. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07907614/registered